Next Healthcare is developing a Precision Medicine approach based on cellular assays. The iPSC enabled platform is designed to accurately predict an individual patient response to a therapeutic intervention in terms of safety and efficacy.
Mission: The Global Depression Epidemic
Depression, Alzheimer’s Disease, Parkinson’s Disease, Chronic Pain, and Chronic Anxiety are the number one causes of human suffering impacting 20% of the human population (WHO, 2017). The socioeconomic burden of Major Depressive Disorder (MDD) is estimated to be greater than $200Bn per year (APA). The Cytonostics™ Platform improves patient outcomes by bettering our understanding of the causal mechanisms of MDD thereby enabling the development and application of therapeutic interventions in a personalized Precision Medicine approach.
Platform: Next Generation Safety and Efficacy
Next HealthCare is going beyond pharmacogenomics assays with the development of Patient Specific Cellular Assays: Cytonostics™. Assay response signatures across data rich, diverse tissue banks enables the in vitro assessment of individualized disease characterization and therapeutic intervention responses to bring the best outcomes for patients. Our first Proof of Concept in Major Depressive Disorder will demonstrate the platform’s ability to model complex diseases with sophisticated models for Precision Medicine aims.
NHC Cytonostics™ Leadership
Chief Executive Officer
In 2007, Dan began organizing capital and experience in the Upper Midwest by organizing successful entrepreneurs into angel investor funds to build on the successful economy and innovation that was outperforming many other areas.
LG funds became one of the first funds in ag, animal, and food tech, beginning in health technology and looking to apply to bring efficiency to food production, building on the leadership in this market during the 90’s by the companies that have been built in this region.
As the ag, animal, food, and health tech market grew, more capital was organized on the coasts, those in the Midwest where production is based remained cautious about which technology would provide long term value that would be embraced by the labor force. The companies began making changes internally to prepare for a market with increased technology while continuing to struggle with labor force challenges.
In 2014, as the LG funds needed to decide when it was time to raise the next fund, and the ag/animal/food/ Dan partnered with experienced entrepreneurs to found FarmQA, to build an IOT platform for agriculture and lead in connecting to the sensors that would measure for increased process control, partnering with the top sensor companies in the space, the top investors in ag tech, and the largest production companies globally.
With deep experience in agriculture in the CIS countries through FarmQA, Dan is close to the distribution challenges and implementation challenges that are the greatest barriers to investment in this space.
He lives in Fargo, ND, with his wife, Sue, and has 2 married children with 5 grandchildren.
Anne Bang, PhD
Dr. Anne Bang joined the Sanford Burnham Prebys Medical Discovery Institute in June 2010 as Director of Cell Biology at the Conrad Prebys Center for Chemical Genomics, a state-of-the-art academic drug discovery center. Her current research efforts are directed at developing patient-specific, induced pluripotent stem cell (iPSC)-based disease models of neurological disease that reflect higher order cellular functions and recapitulate disease phenotypes yet have the throughput and robustness necessary for drug discovery. Her goal is to use these models for target ID and drug screening to develop clinically useful compounds. Prior to joining SBP she served as Director of Stem Cell Research at ViaCyte Inc, where her efforts focused on process optimization and advancing Viacyte’s cell therapy product into development, scaled manufacturing, product characterization, and safety assessment. Dr. Bang received a B.S. from Stanford University, a Ph.D. in Biology from UCSD, and was a post-doctoral fellow at the Salk Institute.
Tom Novak, PhD
Technology Partnerships Advisor
Dr. Tom Novak is currently CSO of Autobahn Labs, a biotech incubator identifying and advancing early stage academic projects that could lead to innovative therapeutics. Prior to that he was Vice President, Life Sciences Business Development, at Cellular Dynamics International (CDI), the world’s leading supplier of stem cell-derived, terminally differentiated cells. In addition, he was the Principal Investigator on CDI’s $16MM grant from the California Institute for Regenerative Medicine (CIRM) to reprogram samples from 3000 patients with a variety of multigenic disorders.
As part of CIRM’s “Human iPSC Initiative” he was also the PI on CDI’s $6.3MM subcontract with the Coriell Institute for Medical Research to provide stocks of iPSC clones for commercial sale. Prior to joining CDI in 2012, Dr. Novak was Senior VP of Research and Development at Fate Therapeutics, a San Diego-based biotech developing small molecules and biologics to induce proliferation and differentiation of adult stem cells to replace tissue lost to aging or disease. From 2001 to 2010, Dr. Novak held a number of positions at Roche Palo Alto, including Senior Director and Head of Discovery Technologies wherein he led a group of >60 scientists with responsibility for all compound screening, cell culture, molecular biology, protein production, and crystallography at that site. In 2009, he was chosen to lead a global team of scientists to evaluate opportunities to utilize stem cells as research tools. This ultimately led to the initiation of three collaborations (CDI, iSTEM, and Harvard Stem Cell Institute) centered around nonclinical safety, neuroscience, and cardiovascular diseases, respectively.
Dr. Novak earned a AB in biology and chemistry, magna cum laude, from Amherst College (Amherst, MA) and received his PhD in molecular biology from Caltech (Pasadena, CA). After completing post-doctoral training in immunobiology at Yale University, he began his pharmaceutical career in 1994 as a research scientist at Wyeth-Ayerst in Princeton, NJ.
Vin Singh is a serial entrepreneur and experienced executive from the life sciences and biotechnology industries. He has extensive start-up experience having founded and built several pioneering companies including BullFrog AI, Inc, which uses machine learning/AI to enable clinical development, Next Healthcare Inc., a personalized diagnostics and adult cell banking service, and MaxCyte Inc., a cell therapy systems company. He was also an executive at GlobalStem Inc. and ThermoFisher Scientific, leading their global cell therapy services business. Vin has a BS in Electrical Engineering from Rutgers University, an MS in Biomedical Engineering from Rensselaer Polytechnic Institute, and an MBA from Johns Hopkins University.